Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Articles
Balloon Kyphoplasty Associated with Less Pain and Greater Mobility
TON - Daily
Christin Melton
In a randomized trial of patients with cancer and vertebral compression fractures (VCFs), balloon kyphoplasty was associated with greater pain relief and better of quality of life than nonsurgical care. According to the authors, patients who received kyphoplasty relied significantly less on pain medication, bed rest, and walking assistance 1 month after the procedure.
James Berenson, MD, founder and president of the Institute for Myeloma and Bone Cancer Research in West Hollywood, California, led the multinational CAFE (Cancer Patient Fracture Evaluation) study, and results were published online in
Lancet Oncology
. In an interview with
The Oncology Nurse
, Berenson said, “Any cancer patient with a vertebral compression, whether the cancer involves the vertebral body or not, would be a candidate for this procedure.” He said balloon kyphoplasty should be performed “without delay” as soon as a symptomatic VCF is diagnosed but added that it might be contraindicated in patients who are not expected to survive long or who are poor surgical risks.
The study enrolled 134 adults with cancer, each of whom had 1 to 3 VCFs. More than half the patients (60%) had multiple myeloma or breast cancer. Investigators randomized 70 patients to undergo balloon kyphoplasty with the option to use nonsurgical care as needed. The remaining 64 patients made up the control group and received only nonsurgical care. All patients were allowed to continue their cancer treatments as prescribed.
To measure improvement in back-specific functionality, the research team administered the Roland-Disability Questionnaire (RDQ) at baseline and again at 1-month follow-up. On the RDQ scale, 0 indicates no disability and 24 represents the maximum level of disability. At baseline, mean RDQ score for the kyphoplasty group was 17.6 compared with 18.2 for the control group. At 1-month follow-up, RDQ scores for the kyphoplasty group declined by a mean of 8.3 points to 9.1 (
P
<.0001). In contrast, RDQ scores declined a mean of 0.1 points for the control arm, to 18.0 (
P
<.0001).
Other standardized tests were used to measure pain, physical and mental health, and performance status. The 10-point pain scale reflected a significant drop of 3.8 points in pain levels for the kyphoplasty group at 7 days postprocedure compared with a 0.3 point drop for the control arm (
P
<.0001). At 1-month, results continued to favor kyphoplasty.
At 1 year, pain assessments for the groups began to converge, and no significant difference in pain levels was observed between the two arms. Berenson said data at the end of the trial were biased because “only a small minority of patients made it to that time point.” He noted that those patients in the study who were alive at 1 year follow-up likely had better quality of life in general, particularly regarding pain levels, compared with the study population as a whole.
Berenson and colleagues noted that 94% of patients treated with kyphoplasty were taking pain medications before the procedure and this had dropped to 52% at 1 month. Medication use remained consistent in the control arm.
After 1 month, patients in the control group were permitted to cross over into the kyphoplasty group, which 38 patients did. This subgroup of patients experienced improvement in pain and function at similar rates and levels to the patients in the original kyphoplasty group. Both kyphoplasty groups maintained their improvement according to 1-year assessments.
The authors hypothesized that the improved function afforded by balloon kyphoplasty might reduce the risk of events such as decubitus ulcers and pneumonia, which are not uncommon in patients with cancer. "A procedure that effectively treats VC Fs for patients with cancer might confer clinical and quality of life benefits beyond treatment of the fracture itself," they wrote.
Balloon kyphoplasty is associated with few adverse effects. Berenson said, “Very rarely, there can be significant extravasation of the cement outside of the cavity in which it is intended.”
The study was limited by its short duration and its open-label design. In an accompanying editorial, David Schiff, MD, and Mary E. Jensen, MD, University of Virginia, Charlottesville, said because of the study design, a placebo effect could not be ruled out. They suggested additional trials were warranted before making the costly surgical procedure standard practice.
Medtronic, which makes the Kyphon balloon kyphoplasty device used in the study provided funding. Berenson and other authors have received consulting fees, honoraria, and research funding from Medtronic. Several authors were Medtronic employees, and one disclosed relationships with Synthes, Orthofix, and Alphtec. Schiff has received consulting fees from Genentech, and Jensen acknowledged consulting fees from Kuros Biosurgery.
Related Items
Guidelines on Screening for Breast, Prostate, and Lung Cancers
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
TON - August 2011 VOL 4, NO 5
Supportive Care
,
Palliative Care
,
Conference Correspondent
Having Evidence-Based Discussions on CAM
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Advanced Practice Nurses Forge New Ground in Radiation Oncology Units
By
Christin Melton
Web Exclusives
Conference Correspondent
Changing the Paradigm of Care for Dying Patients
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Genotyping: Looking at the Future of Lung Cancer Care
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
Web Exclusives
Conference Correspondent
A Review of Investigational Drugs at HOPA
By
Christin Melton
Web Exclusives
Drug Updates
Oncology Nurses Best Positioned to Talk to Patients About Lymphedema
By
Christin Melton
Web Exclusives
Conference Correspondent
Preventing Skeletal-Related Events in Patients
By
Christin Melton
Web Exclusives
Conference Correspondent
View the Latest Issue of TON
Read Issue
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION